Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 12/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
| ▸ | KAT7 | O95251 | 2/20 | 0.37 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.37 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16711314 | 0.85 | GRM5 (0.50) | GRM5NR1H2 | |
| SCHEMBL26645489 | 0.84 | MEN1 (0.44) | GRM5NR1H2MEN1KMT2AESR2 | |
| SCHEMBL26185728 | 0.83 | GRM5 (0.52) | GRM5 | |
| SCHEMBL26645758 | 0.83 | GRM5 (0.43) | GRM5NR1H2MEN1KMT2AESR2 | |
| SCHEMBL16711195 | 0.83 | GRM5 (0.50) | GRM5NR1H2 | |
| SCHEMBL26645025 | 0.82 | CFTR (0.44) | GRM5NR1H2MEN1KMT2A | |
| SCHEMBL30622995 | 0.82 | CFTR (0.44) | GRM5NR1H2MEN1KMT2A | |
| SCHEMBL12307404 | 0.82 | NR1H2 (0.48) | GRM5NR1H2MEN1KMT2AESR2 | |
| SCHEMBL26645099 | 0.81 | GRM5 (0.48) | GRM5NR1H2 | |
| SCHEMBL26645578 | 0.81 | GRM5 (0.50) | GRM5NR1H2MEN1KMT2AESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12595264-B2 | Heterocyclic GLP-1 agonists | GASHERBRUM BIO, INC. (US) | 2026-04-07 | — | — | US | disclosed |
| US-20230331732-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2023-10-19 | — | — | US | disclosed |
| US-20230331732-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2023-10-19 | — | — | US | disclosed |
| US-20230331732-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2023-10-19 | — | — | US | disclosed |
| EP-4211139-A1 | HETEROCYCLIC GLP-1 AGONISTS | Gasherbrum Bio, Inc. (US) | 2023-07-19 | — | — | EP | disclosed |
| CN-116368140-A | Heterocyclic GLP-1 agonists | 加舒布鲁姆生物公司 | 2023-06-30 | — | — | CN | disclosed |
| WO-2022052958-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. (US) | 2022-03-17 | — | — | WO | disclosed |
| WO-2022052958-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. (US) | 2022-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12595264-B2 | Heterocyclic GLP-1 agonists | GLP1R, GIPR, GCGR | GRM5 1354/4885NR1H2 532/4885MEN1 1332/4885 |
| US-20230331732-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | GRM5 2388/4885NR1H2 1786/4885MEN1 526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.